RT Journal Article
T1 Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases.
A1 Agache, Ioana
A1 Annesi-Maesano, Isabella
A1 Bonertz, Andreas
A1 Branca, Francesco
A1 Cant, Andrew
A1 Fras, Zlatko
A1 Ingenrieth, Frank
A1 Namazova-Baranova, Leyla
A1 Odemyr, Mikaela
A1 Spanevello, Antonio
A1 Vieths, Stefan
A1 Yorgancioglu, Arzu
A1 Alvaro-Lozano, Montserat
A1 Barber Hernandez, Domingo
A1 Chivato, Tomás
A1 Del Giacco, Stefano
A1 Diamant, Zuzana
A1 Eguiluz-Gracia, Ibon
A1 van Wijk, Roy Gert
A1 Gevaert, Philippe
A1 Graessel, Anke
A1 Hellings, Peter
A1 Hoffmann-Sommergruber, Karin
A1 Jutel, Marek
A1 Lau, Susanne
A1 Lauerma, Antti
A1 Maria Olaguibel, Jose
A1 O'Mahony, Liam
A1 Ozdemir, Cevdet
A1 Palomares, Oscar
A1 Pfaar, Oliver
A1 Sastre, Joaquin
A1 Scadding, Glennis
A1 Schmidt-Weber, Carsten
A1 Schmid-Grendelmeier, Peter
A1 Shamji, Mohamed
A1 Skypala, Isabel
A1 Spinola, Monica
A1 Spranger, Otto
A1 Torres, Maria
A1 Vereda, Andrea
A1 Bonini, Sergio
K1 allergic diseases
K1 asthma
K1 big data
K1 environmental health
K1 exposome
K1 implementation science
K1 quality criteria
K1 translational research
AB The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients' organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.
YR 2019
FD 2019-06-02
LK http://hdl.handle.net/10668/13929
UL http://hdl.handle.net/10668/13929
LA en
DS RISalud
RD Apr 6, 2025